El interés en corto de Tharimmune da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Tharimmune. Los datos de interés en corto se actualizan cada dos semanas.

Tharimmune (NASDAQ:THAR) Bolsa, Informe de interés en corto

Tharimmune

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Tharimmune Inc

Tharisa PLC

Goldman Sachs analyst Kash Rangan maintains Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) with a Neutral and raises the price target from $72 to $86.

News

Price Target

Analyst Ratings

Goldman Sachs Maintains Neutral on Zoom Video Comms, Raises Price Target to $86

<a href="https://aon.mediaroom.com/2024-11-26-Aon-to-Acquire-In-House-Insurance-Agency-of-Mitsubishi-Chemical-Group-in-Japan">https://aon.mediaroom.com/2024-11-26-Aon-to-Acquire-In-House-Insurance-Agency-of-Mitsubishi-Chemical-Group-in-Japan</a>
&nbsp;
<a href="https://www.aon.com/">Aon plc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), a leading global professional services firm, today announced the signing of a definitive agreement to acquire the in-house insurance agency business of Mitsubishi Chemical Group (MCG) enhancing Aon's risk and health capability offering in Japan.
The in-house insurance agency operates as part of Dia Rix, an in-house business services provider to MCG. Aon will acquire the insurance agency business which provides corporate and personal lines insurance to MCG group companies and employees in Japan. The divestiture will allow MCG to divert resources and investment to its core business while leveraging the global risk management capabilities of Aon to strengthen its global governance.
Following the close of the transaction, the team will transition to Aon's brand and operating model, under the leadership of Tatsuya Yamamoto, head of Aon in Japan, bringing together a combined team of more than 400 colleagues.
Anne Corona, CEO for Aon in Asia Pacific said: "This acquisition reinforces our investment in Japan as an important market for Aon. The existing synergies we share with Dia Rix in terms of capability and culture will allow us to better serve MCG as well as strengthen broader capability and development opportunities for colleagues at the combined firm."
Tatsuya Yamamoto added: "The current changes in the non-life insurance environment in Japan will foster an environment in which global companies like the MCG can focus on their core business by divesting their in-house insurance agency operations, while at the same time supporting their operational efficiency strategies and leveraging a group of experts like Aon to provide an opportunity for more sophisticated global risk management. We are well situated to take this business forward building on our existing capabilities and growth momentum and continue to provide optimal solutions for all our clients in Japan."
The firms will continue to operate independently until the transaction is completed, which is expected in early 2025.

Global

Aon To Acquire In-House Insurance Agency Of Mitsubishi Chemical Group In Japan; No Financial Terms Disclosed

Looking into the current session, Hercules Capital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) shares are trading at $18.86, after a 0.37% decrease. Over the past month, the stock fell by 5.80%, but over the past year, it actually went up by 21.09%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1732631415_0.png" alt="Past Year Chart" />

<h3>How Does Hercules Capital P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Hercules Capital has a lower P/E than the aggregate P/E of 24.2 of the Capital Markets industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732631415_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

HTGC

Price Over Earnings Overview: Hercules Capital

Goldman Sachs analyst Ryan Nash maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Neutral and raises the price target from $59 to $67.

ZION

Goldman Sachs Maintains Neutral on Zions Bancorp, Raises Price Target to $67

Goldman Sachs analyst John Mackay maintains Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) with a Neutral and raises the price target from $45 to $55.

Goldman Sachs Maintains Neutral on Williams Companies, Raises Price Target to $55

Macro Economic Events

Econ #s

Economics

S&P/CS HPI Composite - 20 n.s.a. (MoM) For September -0.4% Vs -0.3% Prior

S&P/CS HPI Composite - 20 n.s.a. (YoY) For September 4.6% Vs 4.7% Est.; 5.2% Prior

President-elect Donald Trump dropped an economic bombshell Monday, announcing plans to slap hefty tariffs on key U.S. trade partners once he returns to the White House <a href="https://www.benzinga.com/topic/donald-trump">on Jan. 20. </a>
Trump pledged 25% tariffs on all Mexican and Canadian imports and an additional 10% levy on Chinese goods, which would remain in place until drugs, and in particular fentanyl, will stop entering the U.S.
&#8220;Thousands of people are pouring through Mexico and Canada, bringing crime and drugs at levels never seen before,&#8221; Trump wrote on Truth Social.
&#8220;On January 20th, as one of my many first executive orders, I will sign all necessary documents to charge Mexico and Canada a 25% tariff on ALL products coming into the United States. This tariff will remain in effect until such time as drugs, in particular Fentanyl, and all illegal aliens stop this Invasion of our country!&#8221;
<h3 class="wp-block-heading">Markets React: Peso And Loonie Hit Hard</h3>
Currency markets were the immediate shock absorber of the news. The Canadian dollar, tracked by the Invesco CurrencyShares Canadian Dollar Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXC#NYSE">FXC</a>), nosedived 0.8%, breaching the 1.41 level against the U.S. dollar — a low not seen since April 2020.
The Mexican peso didn't fare much better, sliding 0.9% to 20.50 against the greenback, while the Chinese yuan slumped 0.4% to a four-month low.
Robin Brooks, economist at the Brookings Institution, warned that this may only be the beginning. "The Mexican Peso is down 1.5% after tonight&#8217;s tariff news from the president-elect. To put this fall in perspective, the Mexican peso fell 10% in just a few days right after Trump's surprise win in 2016. So this fall is small and only the beginning of a sorely needed repricing."
The iShares MSCI Mexico ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWW#NYSE">EWW</a>) fell 1.5% in premarket trading on Tuesday.
James Thorne, a market strategist at Wellington Altus, questioned the practicality of Trump's rhetoric. "Do you really think Mr. Trump will put a 25% tariff on Canadian Sour Crude Oil?" Thorne wrote. "Recall it's mixed with Sweet Shale oil and then refined. Constraint of US refining capacity. Think about that for 1 minute."
<h3 class="wp-block-heading">China In The Crosshairs: Fentanyl And Tariffs</h3>
Trump renewed his criticism of China, blaming the country for America's fentanyl epidemic.
&#8220;I have had many talks with China about the massive amounts of drugs, in particular Fentanyl, being sent into the United States—But to no avail," Trump said. 
He accused Chinese officials of failing to deliver on promises to crack down on drug dealers, stating, "Until such time as they stop, we will be charging China an additional 10% tariff, above any additional tariffs, on all of their many products coming into the United States of America."
The tariffs, according to Trump, would serve as a dual-purpose weapon: curbing illegal drug imports and bolstering his "America First" economic policy.
<h3 class="wp-block-heading">Bill Ackman: Trump Is Using Tariffs As Weapon</h3>
Prominent investor Bill Ackman chimed in on X (formerly Twitter), suggesting that Trump's tariffs are less about trade and more about leverage. 
"To be clear, according to Trump, the 25% tariffs will not be implemented, or if implemented will be removed, once Mexico and Canada stop the flow of illegal immigrants and fentanyl into the U.S.," Ackman said. 
"In other words, Donald Trump is going to use tariffs as a weapon to achieve economic and political outcomes which are in the best interest of America, fulfilling his America First policy."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">To be clear, according to Trump the 25% tariffs will not be implemented, or if implemented will be removed, once Mexico and Canada stop the flow of illegal immigrants and fentanyl into the U.S. In other words, <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> is going to use tariffs as a weapon to achieve… <a href="https://t.co/61oQvCpW92">https://t.co/61oQvCpW92</a>
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1861198845574815947?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42170135/its-the-most-wonderful-time-of-the-year-for-the-stock-market-history-says">&#8216;It&#8217;s The Most Wonderful Time Of The Year&#8217; For The Stock Market, History Says</a></li>
</ul>
Photo: Shutterstock

Asia

Equities

Emerging Markets

Emerging Market ETFs

Currency ETFs

Politics

Forex

Mexican Peso, Canadian Dollar Slide As Ackman Says Trump Will Use Tariffs 'As A Weapon'

USA House Price Index (MoM) For September 0.7% Vs 0.3% Est.; 0.4% Prior

Goldman Sachs analyst Ryan Nash maintains Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) with a Buy and raises the price target from $50 to $60.

Goldman Sachs Maintains Buy on Truist Finl, Raises Price Target to $60

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more
GLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come
KELOWNA, BC / ACCESSWIRE / November 26, 2024 / Lexaria Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXXW#NASDAQ">LEXXW</a>) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following strategic update.
Today's GLP-1 drug market consists primarily of semaglutide (Wegovy&#xAE;, Ozempic&#xAE;, and Rybelsus&#xAE;), owned by Novo Nordisk&#xAE;; and tirzepatide (Zepbound&#xAE;, Mounjaro&#xAE;), owned by Eli Lilly&#x2122;. All five of those drug brands, with the exception of Rybelsus&#xAE;, are administered by injection, whereas Rybelsus&#xAE; is the only oral tablet currently approved by the FDA today. While these two drugs were originally approved by the FDA for diabetes management, weight-loss approvals soon followed and <a href="https://pr.report/4ja2">Wegovy&#xAE; was also approved by the FDA</a> in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke.
Acceptance and use of these two drugs by the public has resulted in unprecedented demand, with estimates of 2024 revenue between them of <a href="https://pr.report/4ja3">~$30 billion, compared to just $300 million in 2018</a>, an increase of 100x or 10,000%.

Biotech

General

LEXX

LEXXW

Lexaria Bioscience Provides Strategic Update; Says Semaglutide Being Investigated For Applications In Heart Disease, Alzheimer's, Liver Disease, And More; GLP-1 Drugs Expected To Generate Multi-Hundreds Of Billions Of Revenues In The Years To Come

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares are trading lower in the <a target="_blank" href="https://www.benzinga.com/24/11/42165679/nio-analyst-sees-tougher-path-to-profitability-downgrades-ev-maker-to-sell-what-you-need-to-know" rel="noreferrer noopener">premarket session on Tuesday.</a>
The Chinese EV manufacturer recently marked its 10th anniversary, with the company&#8217;s founder, chairman, and CEO, William Li, addressing employees through an internal letter.
In the message, Li emphasized the critical importance of the next two years for the company&#8217;s future, <a target="_blank" href="https://cnevpost.com/2024/11/25/nio-10th-anniversary-william-li-internal-letter/" rel="noreferrer noopener">reported</a> CnEV Post. Li outlined key objectives, including the launch of competitive new products and enhancing operational efficiency.
These efforts are aimed at doubling NIO&#8217;s sales in the coming year and achieving profitability by 2026, which he described as non-negotiable goals. Li urged the team to focus their full energy on meeting these targets.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42189572/j-m-smucker-q2-earnings-beat-17-sales-surge-fy25-eps-outlook-boost-more" rel="noreferrer noopener">J.M. Smucker Q2: Earnings Beat, 17% Sales Surge, FY25 EPS Outlook Boost &amp; More</a>
This week, Goldman Sachs analyst Tina Hou downgraded NIO from&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings" rel="noreferrer noopener">Neutral to Sell</a> and lowered the price target from&nbsp;$4.80&nbsp;to&nbsp;$3.90, citing competitive pressures <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings" rel="noreferrer noopener">and a difficult path to profitability ahead</a>.
The analyst notes NIO is unfavorably positioned heading into 2025 given the slow production ramp of&nbsp;Onvo and the company&#8217;s <a target="_blank" href="https://www.benzinga.com/tech/24/11/41703522/ev-maker-nio-marks-battery-swap-network-milestone-rumors-swirl-around-2nd-onvo-electric-suv" rel="noreferrer noopener">limited new model pipeline.</a>
Recently, NIO guided deliveries of 72,000–75,000 units for the fourth quarter, or a 43.9% – <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42084907/nio-q3-earnings-11-6-gain-in-vehicle-deliveries-margins-improve-issues-robust-q4-delivery-outlook" rel="noreferrer noopener">49.9% year-over-year increase.&nbsp;</a>
The company expects&nbsp;fourth-quarter revenue&nbsp;of $2.804 billion &#8211; $2.904 billion, representing 15.0% – 19.2% year-over-year growth.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, NIO stock has lost over 35% in the past year. Investors can gain exposure to the stock via&nbsp;Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>).
Price Action: NIO shares are trading lower by 1.29% to $4.61 premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades" target="_blank" rel="noreferrer noopener">Cathie Wood-Led Ark Invest&#8217;s Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Photo by Sundry Photography on Shutterstock.

Movers

Media

PowerShares Golden Dragon Halter USX China Portfolio

What's Going On With NIO Stock Today?

Goldman Sachs analyst Ryan Nash maintains Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Neutral and raises the price target from $52 to $62.

Goldman Sachs Maintains Neutral on Synovus Finl, Raises Price Target to $62

Goldman Sachs analyst Ryan Nash maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Buy and raises the price target from $29 to $33.

Goldman Sachs Maintains Buy on Regions Finl, Raises Price Target to $33

Goldman Sachs analyst Gabriela Borges maintains Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) with a Neutral and raises the price target from $19 to $21.

PYCR

Goldman Sachs Maintains Neutral on Paycor HCM, Raises Price Target to $21

Goldman Sachs analyst Ryan Nash maintains M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) with a Neutral and raises the price target from $216 to $243.

Goldman Sachs Maintains Neutral on M&T Bank, Raises Price Target to $243

Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) reported better-than-expected third-quarter results and raised its 2024 <a href="https://www.benzinga.com/quote/bbwi/earnings">outlook on Monday.</a>
BBWI&#8217;s third-quarter adjusted earnings per share of 49 cents, beating the analyst consensus of 47 cents. Quarterly sales of $1.610 billion, a growth of 3.1% year-over-year, above the street view of $1.579 billion.
Gina Boswell, CEO of Bath &amp; Body Works, commented, &#8220;Our strong results exceeded the high end of our net sales and earnings per diluted share guidance. As a result, we are raising our full-year guidance to fully reflect this outperformance.&#8221;
The company raised fiscal 2024 guidance and now expects net sales to decline 2.5% – 1.7% (prior view: decline of 4% – 2%), including a 100-basis-point headwind from the 53rd week in 2023. Adjusted earnings per share are projected at $3.15 – $3.28 (prior view $3.06 – $3.26) versus the $3.18 consensus.
Bath &amp; Body Works shares gained 16.5% to close at $35.78 on Monday.
These analysts made changes to their price targets on Bath &amp; Body Works following earnings announcement.
<ul>
<li>Piper Sandler analyst Korinne Wolfmeyer maintained Bath &amp; Body Works with a Neutral and raised the price target from $35 to $36.</li>
<li>Barclays analyst Adrienne Yih maintained Bath &amp; Body Works with an Underweight and raised the price target from $28 to $34.</li>
</ul>
Considering buying BBWI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-1024x562.png" alt="" class="wp-image-665566" style="width:658px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

Earnings

Trading Ideas

BBWI

Bath & Body Works Analysts Boost Their Forecasts After Strong Earnings

Emerald is a leading commercial vehicle manufacturer and seller of refrigerated trucks and vans
The refrigerated Class 3 EV box truck opens new rapidly expanding categories for home delivery, frozen food, grocery and beverage transportation
 &nbsp;
BREA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- via IBN -- <a href="https://www.globenewswire.com/Tracker?data=wFgf3qyya1KMke66r447VNDvrYRea54HMKKRkEIQo7Ly6CoQ822jOQuk85LNxNhZooU03MseZ8fDjALtlgbzIKIt_7OpXeZw6soRqa3qwxk=">Mullen Automotive, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) ("Mullen" or the "Company"), an electric vehicle ("EV") manufacturer, announces today that <a href="https://www.globenewswire.com/Tracker?data=_KqftE2Zw2BKCjE93TpWGt5-j6V6zVcnf-xlK3C_70G2VYB_cBF1YF-BHGPizrPq3GQMdfRLSGcKNe4KxVHmMzA-m4CuMgQqqHWVr8EjgONJBA1I_k_zte6g4XM-yxYU7UW6JQJchokpGnydx1lX_A==">Emerald Transportation Solutions</a> ("Emerald"), a premier commercial refrigeration ("reefer") vehicle upfitter, is working with the Papé Group ("Papé") to develop an advanced reefer upfit for the Mullen THREE, a Class 3 all-electric truck. The refrigerated Class 3 EV box truck opens new rapidly expanding categories for home delivery, frozen food, grocery and beverage transportation.

MULN

Mullen Announces  Emerald Transportation Solutions Is Working With The Papé Group To Develop An Advanced Reefer Upfit For The Mullen THREE, Class 3 All-Electric Truck

Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) will be reporting its third-quarter earnings on Tuesday. Wall Street expects $2.05 in EPS and $24.65 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=DELL" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 93.61% over the past year, 19.48% over the past month.
Let&#8217;s look at what the charts indicate for Dell stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/24/11/42189449/how-to-earn-500-a-month-from-dell-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Dell Stock Ahead Of Q3 Earnings</a>
<h2 class="wp-block-heading">Dell Technical Setup Ahead Of Q3 Earnings&nbsp;</h2>
Dell stock is showcasing a strong bullish trend, with its share price at $144.16 comfortably above the five-day, 20-day and 50-day exponential moving averages. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26084135/Screenshot-2024-11-26-at-6.02.20-PM.png" alt="" class="wp-image-665421" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26084135/Screenshot-2024-11-26-at-6.02.20-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26084135/Screenshot-2024-11-26-at-6.02.20-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
This upward momentum is reinforced by the eight-day simple moving average (SMA) of $137.40, the 20-day SMA at $134.40 and the 50-day SMA at $126.41, all pointing to continued bullish strength. 
Additionally, the stock remains well above its 200-day SMA of $122.23, underscoring long-term upward momentum.
However, while the Moving Average Convergence Divergence (MACD) at 4.36 confirms the bullish trend, and the RSI of 66.17 indicates strong buying momentum, the RSI&#8217;s proximity to overbought territory suggests a risk of bearish consolidation. 
Slight selling pressure also hints at potential near-term volatility. While the trend remains firmly bullish, investors should monitor for signs of cooling off as the stock approaches overbought levels.
<h2 class="wp-block-heading">Analysts See 7% Upside</h2>
Ratings &amp; Consensus Estimates: <a href="https://www.benzinga.com/quote/DELL/analyst-ratings" target="_blank" rel="noreferrer noopener">The consensus analyst rating</a> on Dell stock stands at a Buy currently with a price target of $121.73. Recent analyst ratings from Evercore ISI Group, Wells Fargo and Morgan Stanley suggest an average price target of $154.67 for Dell stock implying a 7% upside.
Price Action: Dell stock closed the trading day Monday at $144.16, down 0.03%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42185644/us-stocks-may-have-a-slow-start-as-trumps-tariff-threat-begins-to-thwart-relief-rally-analysts-remain-positive-on-market-breadth-ai-linked-sectors-and-stocks">US Stocks May Have A Slow Start As Trump&#8217;s Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Tech

DELL

Dell's 93% Rally Hits Q3 Crossroads – What's Next For The Stock?

Canopy Growth Corporation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WEED#TSX">WEED</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) announced on Tuesday that its board of directors has named Luc Mongeau as the company's next chief executive officer, effective Jan. 6, 2025.
Mongeau, a CPG veteran and board member at the Canadian cannabis giant, succeeds CEO David Klein, who announced his plans to retire in August.
Klein, who <a href="https://www.benzinga.com/markets/cannabis/24/08/40417074/head-of-canadian-cannabis-giant-canopy-growth-to-retire-at-the-end-of-this-fy">joined</a> Canopy Growth in January 2020, led the Ontario-based company through transformation and development to meet opportunities within the global cannabis market.
&#8220;Under his leadership, the company established a foundation for multi-market cannabis leadership through its transformation to an asset-light model in Canada and across a range of international markets, including Germany,&#8221; the company said in a press release. &#8220;In addition, Mr. Klein oversaw the launch and advancement of Canopy USA as a first-of-its-kind structure to offer the Company's shareholders unique exposure to the rapid growth and opportunity presented by the U.S. cannabis market ahead of federal permissibility.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40419783/canopy-growth-ceo-departure-leaves-nasdaq-listed-company-poised-for-profit-surge-what-investors-">Canopy Growth CEO Departure Leaves Nasdaq-Listed Company Poised For Profit Surge &#8211; What Investors Need To Know</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">New CEO</h3>
Mongeau, who has over 25 years&#8217; experience as a senior executive, has most recently served as the CEO of North America&#8217;s e-commerce provider for residential and commercial furniture ESolutions Furniture, formerly Bestar-Bush. He previously held the role of president for Weston Foods as well as president of Mars Petcare North America.
Mongeau joined Canopy as an observer in early 2023 and as a board member in Feb. 2024.
The new appointment comes simultaneously with the company's influence extending in the U.S. via Canopy USA, LLC.
The new U.S.-domiciled holding company <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/10/29418334/this-is-how-its-done-why-is-canopys-us-consolidation-plan-blueprint-for-other-canad">first introduced</a> in 2022, represents Canopy Growth's strategy for capturing the U.S. cannabis market. The business strategy, which included acquisitions of Wana Brands and Jetty, as well as holding a minority stake in TerrAscend Corp. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TSND#TSX">TSND</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TSNDF#OTCQX">TSNDF</a>), also includes the acquisition of Acreage Holdings, Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/ACRG#CSE">ACRG</a>, ACRG.B.U)) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ACRHF#OTCQX">ACRHF</a>, ACRDF)) which is expected to close in early 2025, according to Canopy.
<h3 class="wp-block-heading">What's Next</h3>
Mongeau will continue serving as a member of the board in his new role as CEO.
To support an efficient transition, Klein will continue in his role as CEO and a director on the board until the effective date of Mongeau&#8217;s appointment as CEO.
On Jan. 6, 2025, Klein will step down as a member of the board and will shift into a special advisor role until Aug. 31, 2025.
&#8220;I am honored to lead Canopy Growth into this exciting next chapter, and I am confident that our vision, dedication to our consumers, and the commitment of our team members will continue to position us for long-term success and value creation,&#8221; Mongeau said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/11/42100955/the-u-s-cannabis-strategy-no-ones-talking-about-inside-canopys-300m-plan">The U.S. Cannabis Strategy No One&#8217;s Talking About: Inside Canopy&#8217;s $300M Plan</a></li>
</ul>
<h3 class="wp-block-heading">CGC Price Action</h3>
Canopy Growth's shares traded 0.2120% lower at $4.1412 per share during the pre-market session on Tuesday morning.

Cannabis

ACRHF

CSE:ACRG

TSNDF

TSX:TSND

TSX:WEED

WEED

Canopy Growth Names New CEO Who Will Succeed David Klein Amid US Expansion

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) stock is on the move Friday as investors prepare for the company&rsquo;s shares to undergo a reverse split when markets close today.



Tharimmune&nbsp;is enacting a <a href="https://www.nasdaq.com/press-release/tharimmune-announces-1-for-15-reverse-stock-split-2024-05-22">one-for-15 reverse stock split</a> for THAR shares. The shares will still trade under the THAR ticker but will switch to the new CUSIP number 432705309.



Tharimmune&nbsp;notes that this split will see it consolidate every 15 shares of its stock into a single share. The company says that this will leave it with 785,978 shares of THAR stock after the reverse split is complete.



<h2>What&rsquo;s Behind the THAR Reverse Stock Split?</h2>



Tharimmune&nbsp;is moving forward with this reverse stock split to boost the price of its shares. The company wants to boost its share price to reach the $1 minimum bid required to remain on The Nasdaq Capital Market. The stock was trading for 33 cents per share when markets closed yesterday.



Tharimmune&nbsp;wants to remain listed as it&rsquo;s still only a clinical-stage biotechnology company. That means it doesn&rsquo;t have a product to sell just yet. Remaining publicly listed is its goal leading up to a potential drug candidate release.



THAR stock is up 3.7% as of Friday morning ahead of the reverse split. However, the company&rsquo;s shares were down 34.5% year-to-date when markets closed on Thursday.



Investors will find more of the most recent stock market stories below!



We have all of the hottest stock market news traders need to know about on Friday! A few examples include what&rsquo;s happening with shares of Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) and Akanda&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock as well as the biggest pre-market stock movers this morning. All of this news is ready at the links below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-akanda-akan-stock-up-133-today/">Why Is Akanda (AKAN) Stock Up 133% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-may-24th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Tharimmune (THAR) Stock Moving Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sensei Biotherapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101.



SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA. The company notes this has it being developed to treat solid cancer tumors.



The bad news for Sensei Biotherapeutics comes from its <a href="https://www.nasdaq.com/press-release/sensei-biotherapeutics-presents-promising-clinical-data-from-phase-1-dose-escalation">results in this trial</a>. The company notes that only a few patients of the 34 treated showed signs of improvement. That doesn&rsquo;t seem to be sitting well with SNSE stockholders today.



Dr.&nbsp;Shiraj Sen, a principal&nbsp;investigator in the SNS-101 study, said the following about the results.




&ldquo;The data show encouraging signs of clinical activity in a heterogeneous population of patients with advanced solid tumors, where you typically wouldn&rsquo;t expect to see clinical responses, especially in microsatellite stable colorectal and endometrial tumors.&rdquo;




<h2>SNSE Stock Market Movement on Friday</h2>



SNSE stock is seeing a decent amount of trading on Friday morning. This has more than 160,000 shares of the stock changing hands as of this writing. That&rsquo;s closing in on its daily average trading volume of about 208,000 shares.



SNSE stock is down 39.8% as of Friday morning. However, shares were up 83.5% year-to-date when markets closed yesterday.



Investors looking for more of the most recent stock market stories are in luck!



We have all of the hottest stock market news traders need to know about on Friday! That includes what&rsquo;s going on with shares of Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) stock, Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>)&nbsp;stock and Akanda&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock today. All of this info is good to go at the links below!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-akanda-akan-stock-up-133-today/">Why Is Akanda (AKAN) Stock Up 133% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-sensei-biotherapeutics-snse-stock-down-40-today/">Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) stock is falling hard on Friday following the release of new clinical trial data for its metastatic pancreatic cancer treatment.



The company is <a href="https://finance.yahoo.com/news/verastem-oncology-announces-positive-initial-210100621.html">conducting a Phase 1/2 clinical trial</a> of avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel. The results were positive and that initially saw VSTM stock rally higher this morning.



However, investors quickly noticed the safety data included in these results. 19 of the 41 patients in the trial suffered from emergent serious adverse events. That includes 11 with grade &ge;3 events. Among these were blood bilirubin increase, biliary obstruction, febrile neutropenia, pulmonary embolism, sepsis, anaemia, pneumoperitoneum, septic shock, skin infection, malignant neoplasm progression and vomiting.



John Hayslip, Chief Medical Officer at Verastem, said the following about the clinical trial results.




&ldquo;Metastatic pancreatic cancer continues to be a challenging cancer to treat and these data support the intent behind the Therapeutic Accelerator Award that we received from PanCAN to develop new therapies faster and more efficiently than in historical studies.&rdquo;




<h2>VSTM Stock Movement on Friday</h2>



VSTM stock is experiencing heavy trading on Friday alongside this data. That has more than 10 million shares traded as of this writing. This is a massive surge compared to its daily average trading volume of about 134,000 shares.



VSTM stock is down 61.7% as of Friday morning!



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news traders need to know about on Friday! Among that is what has shares of Sensei Biotherapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>), Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) and Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) stock moving today. All of this news is available down below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-sensei-biotherapeutics-snse-stock-down-40-today/">Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-verastem-vstm-stock-down-62-today/">Why Is Verastem (VSTM) Stock Down 62% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Verastem (VSTM) Stock Down 62% Today?

Tharimmune announces $2.08M private placement

Tharimmune files for 1M common stock offering by selling stockholders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Tharimmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) just reported results for the second quarter of 2024.<ul><li>Tharimmune reported earnings per share of -$2.42.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/thar-stock-earnings-tharimmune-for-q2-of-2024/">THAR Stock Earnings: Tharimmune Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

THAR Stock Earnings: Tharimmune Reported Results for Q2 2024

Tharimmune ( ($THAR) ) has provided an announcement. Tharimmune, Inc. has secured an exclusive license from Intract Pharma to develop an oral versi...

Tharimmune Expands Immunology Pipeline with Intract License

Tharimmune ( ($THAR) ) has shared an announcement. Tharimmune, Inc. has announced its intent to acquire Intract Pharma Limited, aiming to purchase ...

Tharimmune Announces Intent to Acquire Intract Pharma

Tharimmune (THAR) presented new TH104 Phase 1 data at the American College of Gastroenterology 2024 Annual Scientific Meeting, underway in Philadel...

Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting

Tharimmune (THAR) presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in ...

Comments

Tharimmune

Interés en corto

Tharimmune (NASDAQ:THAR) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL